<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126005">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835574</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA033672</org_study_id>
    <secondary_id>5R01DA033672</secondary_id>
    <nct_id>NCT01835574</nct_id>
  </id_info>
  <brief_title>Cambodia Integrated HIV and Drug Prevention Implementation Program</brief_title>
  <acronym>CIPI</acronym>
  <official_title>Cambodia Integrated HIV and Drug Prevention Implementation Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cambodia Integrated HIV and Drug Prevention Implementation Program project will
      implement and evaluate an integrated combination HIV prevention intervention: SMARTgirl Plus
      for Cambodian female entertainment and sex workers where non-injection use of amphetamine
      type stimulant (ATS) is high and significantly contributing to HIV risk. SMARTgirl Plus will
      add demonstrated approaches to ATS and HIV prevention (conditional cash transfer (CCT) and
      microfinance (MF) opportunities) into an existing widely disseminated program (SMARTgirl),
      using a stepped wedge randomized cluster design, and assess impacts on HIV related risk
      behavior. Adding CCT and MF to existing HIV prevention programs will broaden the scope of
      the current prevention model which focuses principally on reducing sexual risk through
      condom use and STI care, and uptake of reproductive health services.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>HIV risk behavior</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>amphetamine use</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cross-sectional behavioral risk data will be collected from approximately 1200 eligible participants at 6 timepoints (2 prior to implementation of a substance-use reduction program, two during the program, and two following the program). HIV risk behavior is to be measured by protected versus unprotected sex by partner types.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>HIV</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Cash Transfer</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency Cash Transfer</intervention_name>
    <description>Active amphetamine substance users will be enrolled into a 16-week Contingency Cash Transfer intervention designed to reduce use of amphetamine.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  biological female

          -  speaks Khmer language

          -  self reports 2 or more sex partners and/or transactional sex in last month

          -  able to provide informed consent

        Exclusion Criteria:

          -  male sex

          -  under 18 years of age

          -  unable to speak Khmer language

          -  unable to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Page, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Franciscco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen S Stein, MPH</last_name>
    <phone>(415) 597-9299</phone>
    <email>estein@epi.ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Family Health International</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Song Ngak</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amphetamine-type substance use</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
